<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37422499</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Cellular immunity reflects the persistent symptoms among COVID-19 recovered patients in Japan.</ArticleTitle><Pagination><StartPage>11071</StartPage><MedlinePgn>11071</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11071</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-35505-w</ELocationID><Abstract><AbstractText>Coronavirus disease (COVID-19) often causes persistent symptoms long after infection, referred to as "long COVID" or post-acute COVID-19 syndrome (PACS). This phenomenon has been studied primarily concerning B-cell immunity, while the involvement of T-cell immunity is still unclear. This retrospective study aimed to examine the relationship among the number of symptoms, cytokine levels, and the Enzyme-linked immunosorbent spot (ELISPOT) assay data in patients with COVID-19. To examine inflammatory conditions, plasma interleukin (IL)-6, IL-10, IL-18, chemokine ligand 9 (CXCL9), chemokine ligand 3 (CCL3), and vascular endothelial growth factor (VEGF) levels were analyzed using plasma obtained from COVID-19 recovery patients and healthy controls (HC). These levels were significantly higher in the COVID-19 group than those in the HC group. ELISPOT assays were performed to investigate the correlation between COVID-19 persistent symptoms and T-cell immunity. Cluster analysis of ELISPOT categorized COVID-19 recovery patients in the ELISPOT-high and -low groups, based on the values of S1, S2, and N. The number of persistent symptoms was significantly higher in the ELISPOT-low group than those in the ELISPOT-high group. Thus, T cell immunity is critical for the rapid elimination of COVID-19 persistent symptoms, and its measurement immediately after COVID-19 recovery might predict long-term COVID-19 or PACS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Miyata</LastName><ForeName>Yoshiharu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Bioresource Research and Development, Department of Social/Community Medicine and Health Science, Kobe University Graduate School of Medicine, 1-5-1 Minatojimanakamachi, Chuo-ku, Kobe, 650-0047, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Suzuki</LastName><ForeName>Kohjin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>System Technologies Laboratory, Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-ku, Kobe, 651-2271, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nagano</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iida</LastName><ForeName>Keiji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Diabetes and Endocrinology, Hyogo Prefectural Kakogawa Medical Center, 203, Kanno, Kanno-cho, Kakogawa, Hyogo, 675-8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Takehiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research and Development Division, Sysmex R&amp;D Centre Europe GmbH, Falkenried 88, 20251, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uga</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Central Research Laboratories, Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-ku, Kobe, 651-2271, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Bioresource Research and Development, Department of Social/Community Medicine and Health Science, Kobe University Graduate School of Medicine, 1-5-1 Minatojimanakamachi, Chuo-ku, Kobe, 650-0047, Japan. matsuoh@med.kobe-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="Y">Vascular Endothelial Growth Factor A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Research funding for this study was provided by Sysmex Corporation. K.S., T.H, and H.U. are employees of Sysmex Corporation. The other authors declare no potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>9</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>8</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37422499</ArticleId><ArticleId IdType="pmc">PMC10329673</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-35505-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-35505-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalmedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, et al. Duration of post&#x2013;COVID-19 symptoms is associated with sustained SARS-CoV-2&#x2013; specific immune responses. JCI Insight. 2021 doi: 10.1172/jci.insight.151544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151544</ArticleId><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Goletti D, et al. The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. Clin. Microbiol. Infect. 2021;27:1784&#x2013;1789. doi: 10.1016/j.cmi.2021.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.07.005</ArticleId><ArticleId IdType="pmc">PMC8272618</ArticleId><ArticleId IdType="pubmed">34256141</ArticleId></ArticleIdList></Reference><Reference><Citation>Murugesan K, et al. Interferon-&#x3b3; release assay for accurate detection of severe acute respiratory syndrome coronavirus 2 T-cell response. Clin. Infect. Dis. 2021;73:e3130&#x2013;e3132. doi: 10.1093/cid/ciaa1537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1537</ArticleId><ArticleId IdType="pmc">PMC7665338</ArticleId><ArticleId IdType="pubmed">33035306</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci. Immunol. 2020;5(49):eabd6160. doi: 10.1126/sciimmunol.abd6160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd6160</ArticleId><ArticleId IdType="pubmed">32680954</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad MHS. Immune response scenario and vaccine development for SARS-Cov-2 infection. Int. Immunopharmacol. 2021;94:107439. doi: 10.1016/j.intimp.2021.107439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107439</ArticleId><ArticleId IdType="pmc">PMC7846221</ArticleId><ArticleId IdType="pubmed">33571745</ArticleId></ArticleIdList></Reference><Reference><Citation>Calarota SA, Baldanti F. Enumeration and characterization of human memory t cells by enzyme-linked immunospot assays. Clin. Dev. Immunol. 2013;2013:1&#x2013;8. doi: 10.1155/2013/637649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/637649</ArticleId><ArticleId IdType="pmc">PMC3844203</ArticleId><ArticleId IdType="pubmed">24319467</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, et al. Refining &#x201c;long-COVID&#x201d; by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection. Infect. Dis. Ther. 2021;10:1747&#x2013;1763. doi: 10.1007/s40121-021-00484-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00484-w</ArticleId><ArticleId IdType="pmc">PMC8270770</ArticleId><ArticleId IdType="pubmed">34245450</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 2020;21:1336&#x2013;1345. doi: 10.1038/s41590-020-0782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0782-6</ArticleId><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: A longitudinal cohort study. Lancet Microbe. 2022;3:e348&#x2013;e356. doi: 10.1016/S2666-5247(22)00036-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00036-2</ArticleId><ArticleId IdType="pmc">PMC8942480</ArticleId><ArticleId IdType="pubmed">35345417</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumi T, Harada K. Immune response to SARS-CoV-2 in severe disease and long COVID-19. iScience. 2022;25:104723. doi: 10.1016/j.isci.2022.104723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104723</ArticleId><ArticleId IdType="pmc">PMC9251893</ArticleId><ArticleId IdType="pubmed">35813874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa T, et al. Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19. Cytokine. 2021;148:155618. doi: 10.1016/j.cyto.2021.155618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2021.155618</ArticleId><ArticleId IdType="pmc">PMC8180668</ArticleId><ArticleId IdType="pubmed">34127355</ArticleId></ArticleIdList></Reference><Reference><Citation>Motomura Y, et al. The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells. Nat. Immunol. 2011;12:450&#x2013;459. doi: 10.1038/ni.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2020</ArticleId><ArticleId IdType="pmc">PMC3494493</ArticleId><ArticleId IdType="pubmed">21460847</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36:705&#x2013;716. doi: 10.1016/j.immuni.2012.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.05.008</ArticleId><ArticleId IdType="pmc">PMC3396424</ArticleId><ArticleId IdType="pubmed">22633458</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev. 2000;177:134&#x2013;140. doi: 10.1034/j.1600-065X.2000.17717.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-065X.2000.17717.x</ArticleId><ArticleId IdType="pubmed">11138771</ArticleId></ArticleIdList></Reference><Reference><Citation>Barratt SL, Flower VA, Pauling JD, Millar AB. VEGF (vascular endothelial growth factor) and fibrotic lung disease. Int. J. Mol. Sci. 2018;19:1269. doi: 10.3390/ijms19051269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19051269</ArticleId><ArticleId IdType="pmc">PMC5983653</ArticleId><ArticleId IdType="pubmed">29695053</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H, et al. Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination. Vaccine. 2022;40:2652&#x2013;2655. doi: 10.1016/j.vaccine.2022.03.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.03.057</ArticleId><ArticleId IdType="pmc">PMC8960126</ArticleId><ArticleId IdType="pubmed">35370020</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirato K, et al. Development of genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in Japan. Jpn. J. Infect. Dis. 2020;73:304&#x2013;307. doi: 10.7883/yoken.JJID.2020.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.JJID.2020.061</ArticleId><ArticleId IdType="pubmed">32074516</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/ (Accessed 23 November 2022).</Citation></Reference><Reference><Citation>Noda K, et al. A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Sci. Rep. 2021;11:5198. doi: 10.1038/s41598-021-84387-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84387-3</ArticleId><ArticleId IdType="pmc">PMC7933429</ArticleId><ArticleId IdType="pubmed">33664294</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda Y. Investigation of the freely available easy-to-use software &#x201c;EZR&#x201d; for medical statistics. Bone Marrow Transplant. 2013;48:452&#x2013;458. doi: 10.1038/bmt.2012.244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2012.244</ArticleId><ArticleId IdType="pmc">PMC3590441</ArticleId><ArticleId IdType="pubmed">23208313</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>